BYSANTI
Live / Applied — Third extension granted (statement of use) (as of 29 Jan 2026)
What this means for you
Not registered yet, but its 15 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98181812
- Mark type
- Stylized text
- Filed
- 15 Sept 2023
- Published for opposition
- 11 Jun 2024
- Attorney of record
- Jayme M. Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety; Pharmaceutical preparations for the treatment and prevention of performance anxiety; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of Parkinson's Disease psychosis; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of Autism Spectrum Disorder (ASD); Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of covid-19 pneumonia; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prosecution history
- 30 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Jan 2026 — SOU EXTENSION 3 GRANTED
- 29 Jan 2026 — SOU EXTENSION 3 FILED
- 29 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 28 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jun 2025 — SOU EXTENSION 2 GRANTED
- 27 Jun 2025 — SOU EXTENSION 2 FILED
- 27 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Jan 2025 — SOU EXTENSION 1 GRANTED
- 02 Jan 2025 — SOU EXTENSION 1 FILED
- 02 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 06 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Jun 2024 — PUBLISHED FOR OPPOSITION